Doerner, T., Schulze-Koops, H., Burmester, G. -R., Iking-Konert, C., Schmalzing, M., Engel, A., Kaestner, P., Kellner, H., Kurthen, R., Krueger, K., Rubbert-Roth, A., Schwenke, H., Peters, M. A. and Tony, H. -P. (2019). Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). Clin. Exp. Rheumatol., 37 (6). S. 937 - 946. PISA: CLINICAL & EXPER RHEUMATOLOGY. ISSN 1593-098X
Full text not available from this repository.Abstract
Objective To evaluate early and late responses in biological-naive patients with rheumatoid arthritis (RA) initiating tocilizumab and early tocilizumab non-responders who switched to rituximab. Methods In this open-label, non-randomised phase 3 study, RA patients with inadequate response to conventional synthetic DMARDs received tocilizumab 8 mg/kg intravenously at study begin and weeks 4, 8 and 12. After evaluation at week 16, early responders (Disease Activity Score based on 28 joints-erythrocyte sedimentation rate [DAS28-ESR] <2.6) completed the study; partial responders (DAS28-ESR decrease >1.2 or DAS28-ESR >= 2.6-<= 3.2) were to continue tocilizumab through week 28; non-responders (DAS28-ESR decrease <= 1.2) switched to rituximab (1000 mg, weeks 16 and 18) with safety follow-up through week 66. Results Of 519 patients, 222 (42.8%) achieved early DAS28-ESR remission at week 16; 240 patients continued treatment, 213 (41.0%) received tocilizumab, and 27 ( 5.2%) switched to rituximab. At week 32 DAS28-ESR remission was achieved by 117/213 patients (54.9%) who continued tocilizumab and 4/27 patients (14.8%) who switched to rituximab; good EULAR response was achieved by 66.7% and 25.9% and CDAI remission by 19.2% and 14.8% of patients, respectively. Serious adverse events occurred through week 32 in 45/490 patients (9.2%) who received tocilizumab (serious infections, 2.7%) and through week 66 in 8/27 patients (29.6%) who switched to rituximab. Conclusion Early response to tocilizumab was observed in 42.8% of patients. Half of early partial responders benefitted from continuing tocilizumab. Switching non-responders to rituximab seems feasible. No new safety signals were observed in patients treated with tocilizumab or switched to rituximab.
Item Type: | Journal Article | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Creators: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
URN: | urn:nbn:de:hbz:38-128301 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal or Publication Title: | Clin. Exp. Rheumatol. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Volume: | 37 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Number: | 6 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Page Range: | S. 937 - 946 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Date: | 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Publisher: | CLINICAL & EXPER RHEUMATOLOGY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Place of Publication: | PISA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ISSN: | 1593-098X | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Language: | English | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Faculty: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Divisions: | Unspecified | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subjects: | no entry | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Uncontrolled Keywords: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Refereed: | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
URI: | http://kups.ub.uni-koeln.de/id/eprint/12830 |
Downloads
Downloads per month over past year
Export
Actions (login required)
View Item |